Serotonin reuptake inhibitors

2 papers2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: Canadian Institutes of Health Research and 2 more

Humans2

Outcomes

Cellular senescence

downin humans1

1 study

Serotonin reuptake inhibitors decrease cellular senescence in humans.
“we observed a downregulation of proteins related to senescence, amyloid fiber formation, and platelet activation in the SRI-treated group.”
Humansdepressed pregnant individualsplacentafemalesn = 82
Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis
PloS one11 Dec 2025

Associations

Fall-related hospitalisation

upin humans1

1 study

Serotonin reuptake inhibitors raise the risk of fall-related hospitalisation in humans.
“Pharmacological subgroups associated with higher risk included serotonin reuptake inhibitors, older antiepileptics and drugs with moderate anticholinergic properties.”
Humansprescribed at least one FRID or FRIAR-drug at baselinen = 120,867
Pharmacological stratification of fall-risk-increasing drugs for prevention of fall-related injuries in older adults: a population-based cohort study
Age and ageing4 Sep 2026